AbbVie needs new drugs as its mega-blockbuster Humira won’t bring in billions forever – and after the embarrassing withdrawal of an MS drug earlier this year it has managed to get a ...

The two FDA-approved oral GnRH antagonists – AbbVie and Neurocrine Biosciences' Oriahnn (elagolix) and Myovant's Pfizer-partnered Myfembree (relugolix) – are both combined with hormonal drugs.

The majority of women with uterine fibroids are asymptomatic, consequently get less clinical attention and fibroid tumors often remain undiagnosed. [23,24] Symptomatic women typically complain ...